Polycystic ovary syndrome

Also called PCOS

There are 502 papers on polycystic ovary syndrome in aging research: 100 trials and 84 observational studies in people, 33 in animals, 6 in cells, 268 reviews. The newest story, Nov 5, 2026: “Timed eating helped women with polycystic ovary syndrome lose weight”.

Disease

502 papers study it96 more mention it168 findings

MeSH

42 new papers in 30 daysSee all 598 papers on polycystic ovary syndrome

At a glance

Human studies link polycystic ovary syndrome with higher cardiovascular disease and hypertension risks; a study also links it with higher dementia risk. Diabetes results differ: studies report higher type 2 diabetes risk, while a cohort finds no clear link with progression from normoglycemia or prediabetes to diabetes. Telomere studies report shorter or longer telomeres, or no clear difference, across tissues and populations.

168 findings in 102 papers from 2003 to 2026, 26 of them since April 2026

“Obese PCOS patients had significantly greater GH peak after GHRH+GHRP-6 before fasting.”
Growth-hormone response to combined stimulation with GHRH plus GH-releasing peptide-6 in obese patients with polycystic ovary syndrome before and after short-term fastingJournal of endocrinological investigation2003doi:10.1007/bf03345181
  • Human trial100
  • Humans84
  • Animals33
  • Cells6
  • In silico2

Interventions

8

Melatonin

downin reviews1

1 study
  1. Melatonin decreases polycystic ovary syndrome.

    “MT alleviates polycystic ovary syndrome (PCOS), premature ovarian insufficiency (POI), ovarian injury, and age-related ovarian function decline.”

    Review

    Melatonin in ovarian function and dysfunction: Molecular mechanisms and therapeutic potential

    Journal of ovarian research

More on Melatonin

Trilobatin

downin rats1

1 study
  1. Trilobatin decreases polycystic ovary syndrome in DHEA-induced PCOS rats.

    “TLB administration alleviated estrous cycle disruption, improved ovarian morphology, and normalized serum testosterone, luteinizing hormone, and HOMA-IR index in PCOS rats.”

    Animalsin DHEA-induced PCOS rats

    Trilobatin alleviates polycystic ovary syndrome in rats by targeting SIRT2-Mediated PKM2 acetylation in glycolysis and mitochondrial function

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on Trilobatin

GLP-1 receptor agonists

downin mice1

1 study
  1. GLP-1 receptor agonists decrease polycystic ovary syndrome in mice (DHEA-induced PCOS mice; effect attenuated by co-treatment with cRGDyk).

    “We found that the ameliorating effect of GLP-1RAs on PCOS was attenuated by the combined application of the cRGDyk.”

    AnimalsDHEA-induced PCOS mice; effect attenuated by co-treatment with cRGDyk

    Glucagon-like peptide-1 receptor agonists ameliorate polycystic ovarian syndrome in mice by regulating the irisin level and activating the BMP4-Smad signaling pathway†

    Biology of reproduction

More on GLP-1 receptor agonists

Exercise

downin mice1

1 study
  1. Exercise decreases polycystic ovary syndrome in dehydroepiandrosterone-induced PCOS mice.

    “exercise restored the estrous cycle, reduced ovarian cyst formation, and alleviated ovarian fibrosis and inflammation.”

    Animalsin dehydroepiandrosterone-induced PCOS miceovary

    Exercise attenuates polycystic ovary syndrome development via improved mitochondrial proteostasis

    American journal of physiology. Endocrinology and metabolism

More on Exercise

Alternaria alternata

downin mice1

1 study
  1. Alternaria alternata decreases polycystic ovary syndrome in mice (PCOS).

    “Alternaria alternata (A. alternata) as a metformin-enriched gut fungus that alleviates PCOS in mice”

    AnimalsPCOS

    Intestinal probiotic fungi improve PCOS by sensing metformin signaling and inhibiting gut derived ceramide levels

    Research SquarePreprint

More on Alternaria alternata

Quercetin

downin reviews1

1 study
  1. Quercetin protects against polycystic ovary syndrome.

    “Quercetin has demonstrated therapeutic efficacy in multiple ovarian conditions, including ovarian aging, polycystic ovary syndrome (PCOS), premature ovarian insufficiency (POI), and chemotherapy-induced ovarian damage.”

    Review

    Molecular mechanisms and therapeutic potential of quercetin in ovarian functions

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on Quercetin

Caloric restriction

downin mice1

1 study
  1. Caloric restriction prevents polycystic ovary syndrome in androgen-exposed mice.

    “caloric restriction (CR) in F1 or F2 effectively prevented this transmission by restoring disrupted DNA methylation in oocyte genes”

    Animalsin androgen-exposed mice

    Caloric restriction prevents inheritance of polycystic ovary syndrome through oocyte-mediated DNA methylation reprogramming

    Cell metabolism

More on Caloric restriction

Mesenchymal stem cell-derived apoptotic vesicles

downin mice1

1 study
  1. Mesenchymal stem cell-derived apoptotic vesicles decrease polycystic ovary syndrome in Fasmut and FasLmut mice.

    “systemic administration of mesenchymal stem cell (MSC)-derived apoptotic vesicles (MSC-apoVs) can ameliorate impaired ovarian folliculogenesis, PCOS phenotype, and reduced birth rate in Fasmut and FasLmut mice.”

    Animalsin Fasmut and FasLmut mice

    Mesenchymal stem cell-derived apoptotic vesicles ameliorate impaired ovarian folliculogenesis in polycystic ovary syndrome and ovarian aging by targeting WNT signaling

    Theranostics

More on Mesenchymal stem cell-derived apoptotic vesicles

Effects

45

Telomere length

downin humans2upin humans1no changein humans1

4 studies
  1. Polycystic ovary syndrome is linked with lower telomere length in patients with PCOS compared to controls (p = 0.026).

    “The relative LTL was shorter in the PCOS group than that in the control group (p = 0.026)”

    Humansin patients with PCOS compared to controlsperipheral blood leukocytes

    Shortened Telomere Length in Peripheral Blood Leukocytes From Patients With Polycystic Ovary Syndrome and Insulin Resistance

    The journal of obstetrics and gynaecology research

  2. Polycystic ovary syndrome is linked with higher telomere length in humans (stratified by BMI).

    “When stratified by BMI, LTL was increased in all subgroups in PCOS compared to non-PCOS.”

    Humansstratified by BMIfemales

    Obesity contributes to telomere shortening in polycystic ovary syndrome

    Reproductive sciences (Thousand Oaks, Calif.)

  3. Polycystic ovary syndrome was not clearly linked with telomere length in humans (perimenopausal women) (0.7 ± 0.23 in both groups, p = 0.62).

    “The mean telomere length in both groups was 0.7 (± 0.23), with no statistically significant difference between the two groups (p = 0.62).”

    Humansperimenopausal womenbloodfemales

    Telomere length in women with Polycystic Ovary Syndrome in the perimenopausal

    Research SquarePreprint

  4. Polycystic ovary syndrome is linked with lower telomere length in humans (compared to young age group) (2.39 ± 2.58 vs. 3.96 ± 4.72, p < 0.01).

    “as well as a shorter TL (2.39 ± 2.58 vs. 3.96 ± 4.72; p < 0.01) compared to those of the young age group”

    Humanscompared to young age groupcumulus cells

    Significantly shortened telomere length and altered androgen receptor level in cumulus cells from women with polycystic ovary syndrome

    Taiwanese journal of obstetrics & gynecology

More on Telomere length

Childlessness

no changein humans2

2 studies
  1. Polycystic ovary syndrome was not clearly linked with childlessness in humans.

    “we observed no impact of PCOS susceptibility on childlessness”

    Humans

    Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndrome

    Nature genetics

  2. Polycystic ovary syndrome was not clearly linked with childlessness in humans (PCOS susceptibility).

    “we observed no impact of PCOS susceptibility on childlessness.”

    HumansPCOS susceptibility

    Genomic and proteomic evidence for hormonal and metabolic foundations of polycystic ovary syndrome

    medRxivPreprint

Anti-Müllerian hormone

upin humans2

2 studies
  1. Polycystic ovary syndrome is linked with higher anti-Müllerian hormone in humans (44.4 vs 19.3 pmol/l).

    “Even after the age of 36 years, women with PCOS maintained relatively higher AMH levels (PCOS vs normo-ovulatory: 44.4 vs 19.3 pmol/l).”

    Humansfemales

    Asian women with PCOS have enhanced ovarian reserve and ART outcomes, even at an advanced maternal age: a model for reproductive longevity?

    Human reproduction open

  2. Polycystic ovary syndrome is linked with higher anti-Müllerian hormone in PCOS patients vs controls (7.54 ± 5.8 vs. 2.49 ± 2.0 ng/mL, p < 0.0001).

    “Serum AMH was significantly higher among PCOS patients compared to non-PCOS controls in the non-stratified sample (7.54 ± 5.8 vs. 2.49 ± 2.0 ng/mL, respectively; p < 0.0001)”

    Humansin PCOS patients vs controlsserumfemales

    Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center

    Archives of endocrinology and metabolism

More on Anti-Müllerian hormone

Testosterone

upin humans2

2 studies
  1. Polycystic ovary syndrome is linked with higher testosterone in humans (late reproductive years) (p < 0.001, p = 0.001 and p = 0.032).

    “Testosterone, free androgen index, and fasting insulin were higher in PCOS patients than controls (p < 0.001, p = 0.001 and p = 0.032, respectively).”

    Humanslate reproductive yearsfemales

    Evaluation of muscle and bone composition and function in aging women with polycystic ovary syndrome

    Maturitas

  2. Polycystic ovary syndrome is linked with higher testosterone in humans after 13 years of follow-up.

    “PCOS patients still had higher levels of total testosterone, free androgen index (FAI) and dehydroepiandrosterone sulfate (DHEAS) levels compared to controls.”

    Humansafter 13 years of follow-upfemales

    Alterations of cardiometabolic risk profile in polycystic ovary syndrome: 13 years follow-up in an unselected population

    Journal of endocrinological investigation

More on Testosterone

Metabolic outcome improvement

no changein humans1

1 study
  1. Polycystic ovary syndrome was not clearly linked with metabolic outcome improvement in humans (Adjusted for baseline outcome, age, BMI, race/ethnicity and follow-up time).

    “PCOS status was not associated with differential improvement in any outcome after adjustment.”

    HumansAdjusted for baseline outcome, age, BMI, race/ethnicity and follow-up timeMean 9.6 monthsfemalesn = 919

    Real-World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care Platform

    Endocrinology, diabetes & metabolism

Soluble E-selectin

no changein humans1

1 study
  1. Polycystic ovary syndrome was not clearly linked with soluble E-selectin in humans (women with PCOS compared with healthy controls) (0.61 ± 0.33 vs. 0.61 ± 0.29 ng/mL; P = 0.935).

    “Mean soluble E-selectin levels were comparable between women with PCOS and controls (0.61 ± 0.33 vs. 0.61 ± 0.29 ng/mL, P = 0.935).”

    Humanswomen with PCOS compared with healthy controlsfemales

    Soluble E-selectin and QRISK3-based Cardiovascular Risk Assessment in Women with Polycystic Ovary Syndrome: A Prospective Case-control Study from India

    Journal of human reproductive sciences

More on Soluble E-selectin

Damaged neurons

upin rats1

1 study
  1. Polycystic ovary syndrome increases damaged neurons in middle-aged rats with a history of PCOS (24.25 ± 2.68 vs. 9.50 ± 0.64 in CA1).

    “PCOS rats had a significantly higher number of damaged neurons in the CA1 (24.25 ± 2.68 vs. 9.50 ± 0.64), CA2 (20.75 ± 1.03 vs. 8.25 ± 1.10), CA3 (20.50 ± 1.65 vs. 8.50 ± 1.04), and DG (28.25 ± 1.88 vs. 13.00 ± 1.29) regions of the hippocampus than controls”

    Animalsin middle-aged rats with a history of PCOShippocampus

    Disturbed Spatial Learning and Hippocampal Molecular and Histological Alterations in Middle-Aged Rats with a History of Polycystic Ovary Syndrome

    International journal of endocrinology and metabolism

More on Damaged neurons

Memory performance

no changein rats1

1 study
  1. Polycystic ovary syndrome showed no clear effect on memory performance in middle-aged rats with a history of PCOS.

    “However, memory performance did not differ significantly between PCOS rats and controls.”

    Animalsin middle-aged rats with a history of PCOS

    Disturbed Spatial Learning and Hippocampal Molecular and Histological Alterations in Middle-Aged Rats with a History of Polycystic Ovary Syndrome

    International journal of endocrinology and metabolism

Spatial learning

downin rats1

1 study
  1. Polycystic ovary syndrome impairs spatial learning in middle-aged rats with a history of PCOS (P = 0.03).

    “During training (learning), middle-aged PCOS rats had significantly higher mean latency (22.04 (1.86, 42.22); P = 0.03) and duration (5.62 (1.41, 9.84); P = 0.009) than controls.”

    Animalsin middle-aged rats with a history of PCOS

    Disturbed Spatial Learning and Hippocampal Molecular and Histological Alterations in Middle-Aged Rats with a History of Polycystic Ovary Syndrome

    International journal of endocrinology and metabolism

Coronary artery calcium

upin humans1

1 study
  1. Polycystic ovary syndrome increases coronary artery calcium in humans (relative to controls).

    “Subclinical markers of vascular dysfunction, including increased carotid intima-media thickness, elevated coronary artery calcium, and elevated biomarkers such as asymmetric dimethylarginine and plasminogen activator inhibitor-1, are consistently elevated in women with PCOS relative to controls.”

    Reviewrelative to controls

    Polycystic Ovary Syndrome and Cardiovascular Risk: Mechanisms, Clinical Evidence, and Prevention Strategies

    Cardiology in review

More on Coronary artery calcium

All 45

Upstream

3

Weight loss

downin humans1

1 study
  1. Weight loss decreases polycystic ovary syndrome in women living with gynecological conditions related to obesity (≥5%).

    “clinically meaningful weight loss of ≥5% of total body weight can have benefits for women living with gynecological conditions related to obesity and can improve the symptoms of polycystic ovary syndrome”

    Reviewin women living with gynecological conditions related to obesity

    The clinical relevance of obesity and glucagon-like peptide-1-based therapies for chronic weight management in patients treated by obstetrician-gynecologists and gynecologists: A non-systematic narrative review

    Therapeutic advances in reproductive health

Telomere length

no changein humans1

1 study
  1. Telomere length was not clearly linked with polycystic ovary syndrome in humans.

    “No causal relationships were found between rLTL and PCOS in the Mendelian randomization study.”

    Humans

    Shortened Relative Leukocyte Telomere Length Is Associated With Polycystic Ovary Syndrome and Metabolic Traits

    Endocrinology, diabetes & metabolism

More on Telomere length

SIRT1

downin reviews1

1 study
  1. SIRT1 protects against polycystic ovary syndrome.

    “Research and review on the positive regulation of SIRT1 in ovarian function and its therapeutic effect on PCOS syndrome.”

    Review

    Regulation of SIRT1 in Ovarian Function: PCOS Treatment

    Current issues in molecular biology

More on SIRT1

Associations

80

Cardiovascular disease

upin humans6OR 2.45

6 studies
  1. Polycystic ovary syndrome is linked with a higher risk of cardiovascular disease in humans (adjusted for BMI, smoking status, and physical activity) (OR 2.45, 95% CI 1.78–3.42, p < 0.001).

    “PCOS remained an independent predictor of CVD (OR: 2.45, 95% CI: 1.78–3.42, p < 0.001) even after adjusting for confounders.”

    Humansadjusted for BMI, smoking status, and physical activityfemalesn = 1,000

    SAT-144 Long-Term Cardiovascular Risk in Women with Polycystic Ovary Syndrome: A Retrospective Cohort Analysis

    ENDO 2025 abstract

  2. Polycystic ovary syndrome is linked with a higher risk of cardiovascular disease in humans (compared to age-matched controls) (30%-50% higher (P < 0.0001)).

    “Cardiovascular, cerebrovascular, and peripheral vascular disease were 30%-50% higher, and they occurred 3-4 years earlier in those with PCOS (P < 0.0001)”

    Humanscompared to age-matched controlsfemales

    Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort

    CJC open

  3. Polycystic ovary syndrome predicts cardiovascular disease in humans.

    “Early menarche, polycystic ovary syndrome (PCOS), functional hypothalamic amenorrhea, and exercise-induced secondary amenorrhea are now recognized as predictors of future cardiovascular disease.”

    Reviewfemales

    Fattori di rischio non tradizionali, peculiari del sesso femminile

    Cardiologia Ambulatoriale

  4. Polycystic ovary syndrome is associated with cardiovascular disease in humans (compared to the general population).

    “Women with PCOS are at increased risk for cardiovascular diseases and cardiometabolic disorders compared to the general population.”

    Reviewcompared to the general populationfemales

    Polycystic ovary syndrome and cardiovascular disease risk

    Rational Pharmacotherapy in Cardiology

  5. Polycystic ovary syndrome raises the risk of cardiovascular disease in humans.

    “women who have experienced inflammatory-type conditions such as polycystic ovarian syndrome (PCOS), gestational diabetes or pre-eclampsia, have a cardiometabolic phenotype that pre-disposes to increased risk of myocardial infarction, stroke and coronary heart disease.”

    Reviewfemales

    Unique cardiometabolic factors in women that contribute to modified cardiovascular disease risk

    European journal of pharmacology

  6. Polycystic ovary syndrome raises the risk of cardiovascular disease in humans (PCOS).

    “are therefore at higher risk for cardiovascular disease morbidity and mortality, a risk that increases after menopause.”

    ReviewPCOSfemales

    Polycystic ovary syndrome: A review of diagnosis and management, with special focus on atherosclerotic cardiovascular disease prevention

    Journal of clinical lipidology

More on Cardiovascular disease

Telomere length

no changein humans3downin humans2OR 0.503

5 studies
  1. Telomere length is linked with a lower risk of polycystic ovary syndrome in humans (compared to shorter LTL).

    “Individuals with relatively longer LTL have a lower risk of disease compared to those with shorter LTL.”

    Humanscompared to shorter LTL

    Shortened Telomere Length in Peripheral Blood Leukocytes From Patients With Polycystic Ovary Syndrome and Insulin Resistance

    The journal of obstetrics and gynaecology research

  2. Telomere length is linked with a lower risk of polycystic ovary syndrome in humans (adjusted for age, history of smoking and other cardiometabolic traits) (OR: 0.503; 95% CI: 0.342-0.730; p < 0.001).

    “Longer rLTL was associated with a lower risk of PCOS after adjusting for age, history of smoking and other cardiometabolic traits (OR: 0.503; 95% CI: 0.342-0.730; p < 0.001).”

    Humansadjusted for age, history of smoking and other cardiometabolic traitsfemales

    Shortened Relative Leukocyte Telomere Length Is Associated With Polycystic Ovary Syndrome and Metabolic Traits

    Endocrinology, diabetes & metabolism

  3. Polycystic ovary syndrome is associated with telomere length in humans (coefficient 0.05, 95% CI -0.05 to 0.15).

    “telomere length (PCOS coefficient, 0.05; 95% CI, -0.05 to 0.15)”

    Humansleukocyte cellsfemales

    Association of polycystic ovary syndrome with endothelial health, cardiovascular risk, and cellular aging

    Fertility and sterility

  4. Polycystic ovary syndrome is associated with telomere length in humans (adjusted for BMI, smoking, alcohol consumption and socioeconomic status) (P > 0.4).

    “Women with PCOS had similar mean LTL at ages 31 and 46 (P > 0.4 for both).”

    Humansadjusted for BMI, smoking, alcohol consumption and socioeconomic statusfemales

    Polycystic ovary syndrome and leukocyte telomere length: cross-sectional and longitudinal changes

    European journal of endocrinology

  5. Polycystic ovary syndrome is associated with telomere length in humans (comparing PCOS patients with the control group) (SMD = 0.25, 95% CI: -0.01, 0.51, p = .06).

    “There was a non-significant leukocyte telomere length difference (SMD = 0.25, 95% CI: -0.01, 0.51, p = .06, I2 = 81%, Tau2 = 0.08) comparing PCOS patients with the control group.”

    Reviewcomparing PCOS patients with the control groupfemalesn = 2,109

    Leukocyte telomere length in women with and without polycystic ovary syndrome: a systematic review and meta-analysis

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

More on Telomere length

Type 2 diabetes

upin humans4OR 2.9

4 studies
  1. Polycystic ovary syndrome is linked with a higher risk of type 2 diabetes in humans (compared to age-matched controls) (2-3 fold higher (P < 0.001)).

    “The prevalence of obesity, dyslipidemia, nonalcoholic fatty liver disease, and type 2 diabetes was 2-3 fold higher in those with PCOS (P < 0.001).”

    Humanscompared to age-matched controlsfemales

    Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort

    CJC open

  2. Polycystic ovary syndrome raises the risk of type 2 diabetes in humans (OR 2.9).

    “These studies report an almost 3-fold increased risk of Type 2 diabetes (OR 2.9)”

    Review

    Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk

    Journal of internal medicine

  3. Polycystic ovary syndrome is associated with type 2 diabetes in humans.

    “Polycystic ovary syndrome was identified as a multisystemic endocrine-metabolic disorder closely linked to obesity, chronic inflammation, hyperandrogenism, and future risk of type 2 diabetes mellitus.”

    Reviewfemales

    Beyond Reproduction: The Systemic Role of Female Hormones in Cardiometabolic Health

    IECCMEXICO

  4. Polycystic ovary syndrome raises the risk of type 2 diabetes in women with PCOS later in life.

    “association of obesity (particularly the abdominal phenotype) and PCOS renders affected women more susceptible to develop type 2 diabetes mellitus (T2DM)”

    Reviewin women with PCOS later in lifefemales

    Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age

    Annals of the New York Academy of Sciences

More on Type 2 diabetes

Metabolic syndrome

upin humans3no changein humans1RR 1.48

4 studies
  1. Polycystic ovary syndrome is associated with metabolic syndrome in humans (OR 1.29, 95% CI 0.31-5.44).

    “metabolic syndrome (odds ratio for PCOS, 1.29; 95% CI, 0.31-5.44)”

    Humansfemales

    Association of polycystic ovary syndrome with endothelial health, cardiovascular risk, and cellular aging

    Fertility and sterility

  2. Polycystic ovary syndrome is linked with a higher risk of metabolic syndrome in humans (early reproductive age).

    “At early reproductive age, PCOSw showed higher BMI, WC, and VAI and a higher prevalence of MS compared to Cw (p<0.05).”

    Humansearly reproductive agefemales

    Metabolic profile in women with polycystic ovary syndrome across adult life

    Metabolism: clinical and experimental

  3. Polycystic ovary syndrome is associated with metabolic syndrome in humans (48% higher risk; RR 1.48, 95% CI 1.15–1.90).

    “For MetS, PCOS increased risk by 48% (RR: 1.48, 95% CI: 1.15-1.90)”

    Reviewfemales

    Polycystic ovary syndrome with metabolic syndrome and diabetes: a systematic review and meta-analysis

    Journal of ovarian research

  4. Polycystic ovary syndrome is associated with metabolic syndrome in adult fertile age.

    “obesity and MS may affect more than half these women”

    Reviewin adult fertile agefemales

    Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age

    Annals of the New York Academy of Sciences

More on Metabolic syndrome

Anti-Müllerian hormone

upin humans3

3 studies
  1. Polycystic ovary syndrome is associated with anti-Müllerian hormone in humans (50 women with PCOS compared with 50 controls) (6.08 ± 1.67 vs 2.49 ± 0.80 ng/mL).

    “Women with PCOS had significantly higher anti-Müllerian hormone levels (6.08 ± 1.67 vs 2.49 ± 0.80 ng/mL)”

    Humans50 women with PCOS compared with 50 controlsfemalesn = 100

    Does Polycystic Ovary Syndrome Predispose to Premature Ovarian Insufficiency? A Comparative Study of Ovarian Reserve Markers in Reproductive-Age Women

    International Journal of Clinical Obstetrics and Gynaecology

  2. Anti-Müllerian hormone predicts polycystic ovary syndrome in humans (AMH diagnostic cutoff of 1.17 ng/mL) (AUC 0.71 (95% CI 0.60–0.83)).

    “An AMH cutoff of 1.17 ng/mL showed moderate diagnostic reliability for diagnosing PCOS in aging women, with an area under curve of 0.71 (95% CI:0.60-0.83).”

    HumansAMH diagnostic cutoff of 1.17 ng/mLfemales

    Structural and hormonal changes in the ovaries of women with polycystic ovary syndrome and healthy controls: a 13-year prospective study in an unselected population

    Reproductive biology and endocrinology : RB&E

  3. Polycystic ovary syndrome is associated with anti-Müllerian hormone in humans (PCOS compared with healthy controls at follow-up).

    “but retained higher levels of AMH, TT, FAI, and DHEAS than controls.”

    HumansPCOS compared with healthy controls at follow-up13 yearsfemales

    Structural and hormonal changes in the ovaries of women with polycystic ovary syndrome and healthy controls: a 13-year prospective study in an unselected population

    Reproductive biology and endocrinology : RB&E

  4. Polycystic ovary syndrome is associated with anti-Müllerian hormone in humans (Women of Indian origin attending fertility clinics).

    “We found a direct correlation of high AMH and women with polycystic ovary syndrome”

    HumansWomen of Indian origin attending fertility clinicsfemales

    Effect of Reproductive and Lifestyle Factors on Anti-Mullerian Hormone Levels in Women of Indian Origin

    Journal of human reproductive sciences

More on Anti-Müllerian hormone

Cellular senescence

upin humans1upin silico1upin reviews1

3 studies
  1. Polycystic ovary syndrome is associated with cellular senescence in humans.

    “was significantly higher in the ovaries of patients with PCOS”

    Humansovary

    Cellular senescence of granulosa cells in the pathogenesis of polycystic ovary syndrome

    Molecular human reproduction

  2. Cellular senescence raises the risk of polycystic ovary syndrome.

    “contribute to the pathogenesis of polycystic ovary syndrome (PCOS).”

    Review

    Cellular senescence in the pathogenesis of ovarian dysfunction

    The journal of obstetrics and gynaecology research

  3. Polycystic ovary syndrome is associated with cellular senescence in silico (polycystic ovary syndrome) (73 ARDEGs).

    “Here, we identified 73 aging-related differential expression genes (ARDEGs) by intersecting DEGs in PCOS and senescence-related gene set.”

    In silicopolycystic ovary syndrome

    Identification and validation of senescence-related genes in polycystic ovary syndrome

    Journal of ovarian research

More on Cellular senescence

Hypertension

upin humans2RR 2.285

2 studies
  1. Polycystic ovary syndrome is associated with hypertension in humans (RR 2.285; OR 2.347).

    “Also, had higher risk of hypertension (RR 2.285, OR 2.347, p<0.0001).”

    Humansfemalesn = 23,000

    Cardiovascular risk in under-represented minority women with PCOS: evidence for subclinical cardiac remodeling and HFpEF predisposition

    ESC Congress 2026 abstract

  2. Polycystic ovary syndrome is linked with a higher risk of hypertension in humans (compared to age-matched controls) (20%-40% higher (P < 0.0001)).

    “The prevalences of hypertension, renal disease, gastrointestinal disease, eating disorders, mental illness, depression-anxiety, rheumatoid arthritis, respiratory infections, and all malignancies were 20%-40% (P < 0.0001) higher in those with PCOS”

    Humanscompared to age-matched controlsfemales

    Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort

    CJC open

More on Hypertension

Gestational diabetes mellitus

upin humans2OR 1.61

2 studies
  1. Polycystic ovary syndrome is linked with a higher risk of gestational diabetes mellitus in humans (adjusted for covariates) (adjusted OR 1.61 (95% CI 1.49-1.73)).

    “Corresponding adjusted ORs (95% CI) were 1.18 (1.11-1.26), 1.26 (1.16-1.37), 1.61 (1.49-1.73) and 1.31 (1.25-1.37), respectively.”

    Humansadjusted for covariates

    Polyendocrine Metabolic Ovarian Syndrome and the Entire Spectrum of Gestational Dysglycemia: A Population-Based Cohort Study

    Diabetes, obesity & metabolism

  2. Polycystic ovary syndrome raises the risk of gestational diabetes mellitus in humans during pregnancy.

    “Pregnancy in women with PCOS is associated with a higher risk of complications including gestational diabetes, particularly in those with obesity.”

    Reviewduring pregnancyfemales

    POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: The impact of polycystic ovary syndrome on reproductive health: a narrative review

    Reproduction (Cambridge, England)

More on Gestational diabetes mellitus

Breast cancer

mixedin humans2

2 studies
  1. Polycystic ovary syndrome is associated with breast cancer in humans.

    “Current evidence indicates a possible modest association between PMOS/PCOS and breast cancer risk, although findings remain inconclusive.”

    Review

    Polycystic ovary syndrome and breast cancer risk: a systematic review

    European journal of obstetrics, gynecology, and reproductive biology

  2. Polycystic ovary syndrome is associated with breast cancer in humans.

    “The interrelation between PCOS and breast carcinoma remains ambiguous due to inconsistent and inconclusive epidemiological evidence.”

    Review

    PCOS and breast cancer risk: hormonal modulation and epidemiological trends

    Reproductive health

More on Breast cancer

Metabolic dysfunction-associated steatotic liver disease

upin humans2

2 studies
  1. Polycystic ovary syndrome raises the risk of metabolic dysfunction-associated steatotic liver disease in humans (>2-fold).

    “Polycystic ovary syndrome (PCOS) and the menopause increase MASLD prevalence by more than twofold.”

    Reviewfemales

    Relationship between MASLD and women's health: A review

    Women's health (London, England)

  2. Polycystic ovary syndrome raises the risk of metabolic dysfunction-associated steatotic liver disease in premenopausal women.

    “The factors that affect the likelihood of developing NAFLD in a premenopausal woman are an imbalance of sex hormones (especially in estradiol and androgen), microbiome dysregulation, insulin resistance, early menarche”

    Reviewin premenopausal womenfemales

    Premenopausal Syndrome and NAFLD: A New Approach Based on Gender Medicine

    Biomedicines

More on Metabolic dysfunction-associated steatotic liver disease

Growth hormone response to GHRH plus GHRP-6

upin humans1

1 study
  1. Polycystic ovary syndrome is associated with growth hormone response to GHRH plus GHRP-6 in humans (before fasting, obese PCOS vs obese controls).

    “Obese PCOS patients had significantly greater GH peak after GHRH+GHRP-6 before fasting.”

    Human trialbefore fasting, obese PCOS vs obese controlsfemales

    Growth-hormone response to combined stimulation with GHRH plus GH-releasing peptide-6 in obese patients with polycystic ovary syndrome before and after short-term fasting

    Journal of endocrinological investigation

More on Growth hormone response to GHRH plus GHRP-6

All 80

Trial sponsors

Funding

17 grants since 2017

National Institute of Child Health and Human Development$5.1MNational Institute of Diabetes and Digestive and Kidney Diseases$4.5MJapan Society for the Promotion of Science¥9.4M

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Polycystic ovary syndrome is associated with cardiovascular disease, type 2 diabetes and dementia in human studies, while a 13-year follow-up reports no difference in cardiometabolic risk. Telomere results differ across tissues and populations, with shorter, longer and unchanged lengths reported. Human studies also associate the syndrome with later menopause.

  2. Summary rewritten as its findings changed.

    As it read before

    In one study, middle-aged rats with a history of polycystic ovary syndrome show increased hippocampal neuronal damage and impaired spatial learning, but unchanged memory performance.

  3. Summary written from the findings.

Latest

Dec 2025: 7Jan 2026: 42Feb 2026: 30Mar 2026: 33Apr 2026: 14May 2026: 15Jun 2026: 14Jul 2026: 26Aug 2026: 22Sep 2026: 16Oct 2026: 33Nov 2026: 13265 papers in 12 months
Obstetrical & Gynecological Survey

Timed eating helped women with polycystic ovary syndrome lose weight

In a six-month randomized trial of 76 women, eating within six hours reduced weight versus controls but did not significantly outperform daily calorie restriction.In a six-month randomized trial of 76 women, eating within six hours reduced weight versus controls but did not significantly outperform daily calorie restriction.

Randomized trial · 76 peoplePolycystic ovary syndrome

See all 598 papers on polycystic ovary syndrome